Bell, Alexander J.
Pal, Ravi
Labaki, Wassim W.
Hoff, Benjamin A.
Wang, Jennifer M.
Murray, Susan
Kazerooni, Ella A.
Galban, Stefanie
Lynch, David A.
Humphries, Stephen M.
Martinez, Fernando J.
Hatt, Charles R.
Han, MeiLan K.
Ram, Sundaresh
Galban, Craig J.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (T32 HL 007749, R01 HL150023, R01 HL139690)
Article History
Received: 9 January 2024
Accepted: 13 February 2024
First Online: 28 February 2024
Declarations
:
: Our study was a secondary analysis of data from COPDGene (ClinicalTrials.gov: NCT00608764), a large Health Insurance Portability and Accountability Act-compliant prospective multi-center observational study. In Phase 1 (2007–2012) and Phase 2 (2013–2017), 5-year follow-up, written and informed consent was obtained from all participants and the study was approved by local institutional review boards of all 21 centers.
: Our study did not require consent for publication from individuals as it was a secondary analysis of data from COPDGene (ClinicalTrials.gov: NCT00608764). Written and informed consent for the COPDGene study was obtained from all participants and the study was approved by local institutional review boards of all 21 centers. For our study, data from COPDGene was anonymized and our authors had no access to identifying information for COPDGene study participants.
: Wassim W. Labaki reports personal fees from Continuing Education Alliance. Benjamin A. Hoff and Craig J. Galban are co-inventors and patent holders of tPRM, which the University of Michigan has licensed to Imbio, LLC. Craig J. Galban is co-inventor and patent holder of PRM, which the University of Michigan has licensed to Imbio, LLC. Benjamin A. Hoff and Craig J. Galban have financial interest in Imbio, LLC. Charles R. Hatt is employed by Imbio, LLC. David A. Lynch reports funds paid to the institution from NIH and personal payments from Boehringer Ingelheim. MeiLan K. Han reports personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron, Amgen, UpToDate, Altesa Biopharma, Medscape, NACE, MDBriefcase and Integrity. She has received either in kind research support or funds paid to the institution from the NIH, Novartis, Sunovion, Nuvaira, Sanofi, AstraZeneca, Boehringer Ingelheim, Gala Therapeutics, Biodesix, the COPD Foundation and the American Lung Association. She has participated in Data Safety Monitoring Boards for Novartis and Medtronic with funds paid to the institution. She has received stock options from Meissa Vaccines and Altesa Biopharma. For the remaining authors none were declared.